mAb Development

Apr 01, 2016
BioPharm International
The authors review the technologies that may help bioprocessing become a truly continuous operation and present case studies that could contribute to the integration of upstream and downstream platforms.
Mar 31, 2016
Adheren relies on chemical modifications, rather than genetic engineering, to create its cell-based immunotherapies.
Mar 22, 2016
The BARDA-supported monoclonal antibody was approved both as a treatment after anthrax exposure and as an anthrax prophylactic.
Mar 01, 2016
BioPharm International
Experts in the field share some best practices for optimizing process economics in biomanufacturing.
Feb 17, 2016
FDA fast-tracked the monoclonal antibody based on early clinical data from a Phase I trial.
Feb 01, 2016
BioPharm International
The authors review the status of expression of antibodies in microbial hosts and present the recent advances in the production of aglycosylated antibodies in bacteria.
Jan 04, 2016
BioPharm International
BioPharm highlights the monoclonal antibodies that may gain United States regulatory approval in 2016.
Dec 10, 2015
The company will in-license a novel antibody, which has a conformation that is associated with increased therapeutic efficacy.
Oct 29, 2015
By BioPharm International Editors
The novel antibody-engineering platform works differently than most of the currently employed antibody-modifying technologies, according to UM Baltimore.
Sep 28, 2015
By BioPharm International Editors
Although the Committee for Medicinal Products for Human Use (CHMP) gave Blincyto a positive opinion, full approval of the drug in the EMA will rely on additional clinical studies.
lorem ipsum